Competitive Technologies, Inc. (AMEX:CTT - News) announced today that they will be making presentations in California to the investment communities in San Diego, Newport Beach and San Francisco, recognizing the increased investor interest from individuals and institutions:

 Thursday    June 19    San Diego        Westgate Hotel
 Friday      June 20    Newport Beach    The Daily Grill
 Wednesday   June 25    San Francisco    Le Meridien Hotel

"We will be in California for the BIO International Convention in San Diego from June 17 - 20 to display our pain management therapy device, a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs,'' said John B. Nano, CTT's Chairman, President and CEO.

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that they will display their pain management therapy device at the BIO International Convention in San Diego, CA from June 17 - 20 (http://www.bio2008.org). The convention is the world's largest gathering of biotechnology, pharmaceutical, nanotechnology, and medical device leaders.

Competitive Technologies, Inc. (AMEX:CTT - News) today announced financial results for the three and nine months ended April 30, 2008.

The financial results for the third quarter ended April 30, 2008 are a net loss of approximately $1.0 million, or $0.12 per share, a 50% reduction in the net loss when compared to the net loss of approximately $2.0 million, or $0.25 per share, for the prior year quarter. The net loss for the nine-month period ending April 30, 2008 is $4.9 million, or $0.60 per share, a 28% reduction in the net loss when compared to the net loss of $6.7 million, or $0.84 per share, for the prior-year period. Cash position at quarter end was $2.9 million, with no long-term debt.

Daily management and execution of an IR strategy is paramount to the success of a campaign. To be effective, an IR program requires dedicated personnel to co-ordinate both lead generating efforts and communications efforts that must go "beyond the press release". Proactive communications, press release drafting and daily interaction with investors are just some of the tactics employed. By watching the metrics that coincide with our clients programs, we have been able to maximize our efforts, and become more productive at raising awareness.
(See chart below)

Competitive Technologies is pleased to announce the official unveiling of the Pain Management Therapy System at Pharma Finance 2008.

The therapy device, from the research of CTT client Professor Giuseppe Marineo of Delta Research & Development in Rome, treats oncological and neuropathic pain that has proven resistant to traditional drug protocols.

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that it has obtained exclusive North American distribution rights to a compressed air drying device from SECO Engineering S.r.l. of Rome, Italy. The patented air-purifying device extends the life of pneumatic components by eliminating water condensation, oil residues, and solid particles that are contaminants present in compressed air lines. CTT signed the agreement with SECO for their technology, and will identify industrial supply distribution agents for the product for its use wherever pneumatic air is important.

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that it has provided a pain therapy device to the major cancer hospice center, The Scientific Institute of Romagna for the Study and Treatment of Cancer (IRST). John B. Nano, CTT's Chairman, President and CEO and Prof. Giancarlo Elia Valori of the Italian business development group, Sviluppo Lazio S.p.A made the presentation in a ceremony today Thursday, May 22, 2008 in Rome. The device was presented during the Gala Dinner of Pharma Finance 2008 sponsored by the Zangani Investor Community(tm). Prof. Valori highlighted how this pain device known as a ``merciful machine'' will assist terminally ill patients, providing a dignified end of life. The device will be used for pain therapy and for demonstration during the training of staff of other health care centers.

University of Connecticut Health Center and Competitive Technologies, Inc. (AMEX:CTT - News) announced today that Dr. Eric Secor Jr., assistant professor from the Department of Immunology at the University's School of Medicine in Farmington, has been awarded a multiyear $750,000 K-08 Career Development Award from the National Institutes of Health (NIH) and the National Center of Complementary and Alternative Medicine (NCCAM). Dr. Secor's grant is a continuing study of anti-inflammatory and immunomodulatory effects of bromelain, a natural botanical product, in asthma. This work has originated in association with Dr. Roger Thrall, a prominent asthma researcher and recipient of several NIH grants including his current $1.8 million grant to investigate the mechanisms of allergic asthma. CTT has been providing basic funding for Dr. Secor's research to support his proposal to the NIH.

Competitive Technologies, Inc. (AMEX:CTT - News) announced that John B. Nano, CTT's Chairman, President and CEO in an interview today discussed CTT's exclusive worldwide distribution rights to its pain therapy device. The device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. The CTT device has Medical Device CE certification from the European Union allowing European sales and CTT has applied for FDA 510(k) medical device authorization for U.S. sales of the device. The patented device uses a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin. The complete interview may be heard at http://www.zangani.com/webcasts/20080514/ctt

Zangani Investor Community(TM) interviews John B. Nano, Chairman, President and Chief Executive Officer of Competitive Technologies, Inc.

Mr. Nano discusses CTT's first successful transaction of it's new technology, developed in Italy for pain management, and how the company is working to commercialize additional business opportunities in Italy.

CTT to Display the Device At APS Meeting in Tampa

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that it has applied for FDA 510(k) medical device authorization for U.S. sales of its pain management therapy device. The CTT device has Medical Device CE certification from the European Union allowing European sales for this non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. CTT has exclusive worldwide rights to this patented device.

CTT will launch and display the device in the U.S. at the American Pain Society's (APS) 27th Annual Scientific Meeting in Tampa, FL on May 8 and 9, 2008 (http://www.ampainsoc.org). The APS is a multidisciplinary community that brings together scientists, clinicians and other professionals to increase the knowledge of pain and transform public policy and clinical practice to reduce pain-related suffering.

John Nano, Chairman & CEO of Competitive Technologies, explains their new breakthrough pain management system.

The therapy device, from the research of CTT client Professor Giuseppe Marineo of Delta Research & Development in Rome, treats oncological and neuropathic pain that has proven resistant to traditional drug protocols.

The non-invasive treatment from the research of CTT client Professor Marineo has already been used with successful results in seven hospitals in Italy on over 2,000 patients suffering from intense drug-resistant pain. The device has received Medical Device CE certification from the European Union as an approved electronic-analgesic apparatus. The treatment is performed by applying surface electrodes to the skin to simultaneously treat multiple pain areas.

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that is has signed a letter of agreement with a billion-dollar European healthcare company in anticipation of granting them European distribution rights for CTT's pain management therapy device. The device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. It has Medical Device CE certification from the European Union allowing European sales.

Competitive Technologies, Inc. (AMEX:CTT - News) held its annual meeting of shareholders today at the American Stock Exchange in New York City. John B. Nano, CTT's Chairman, President and CEO discussed the company's performance and its portfolio of technologies. The full slide presentation is available under Investors on the CTT website: http://www.competitivetech.net.

Competitive Technologies, Inc. (AMEX:CTT - News) today announced financial results for the three and six months ended January 31, 2008.

The financial results for the second quarter ended January 31, 2008 are a net loss of approximately $1.3 million, or $0.16 per share, a 64% improvement when compared to the net loss of approximately $3.6 million, or $0.44 per share, for the prior year quarter. The net loss for the six-month period ending January 31, 2008 is $3.9 million, or $0.47 per share, a 17% improvement when compared to the net loss of $4.7 million, or $0.59 per share, for the prior-year period. Cash position at quarter end was $4.5 million, with no long-term debt.

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that their client Medical College of Georgia Research Institute (MCGRI), and MCGRI's collaborator University of Georgia (UGA), and Percept BioSciences have entered into an agreement to obtain an exclusive worldwide license to develop and commercialize a patented library of novel compounds that have demonstrated superior efficacy in established non-human primate models of cognition and attention for human health applications. The technology is from the work of Drs. Jerry Buccafusco and Alvin Terry, Jr. at MCG, and Dr. J. Warren Beach at UGA. The agreement allows for varying levels of compensation to MCGRI and UGA. CTT will share in the payments to MCGRI.

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that its Board of Directors has set Friday, April 18, 2008 as the date for their 2008 Annual Meeting of Shareholders.

Shareholders at the close of business on March 14, 2008, the record date, are entitled to receive notice of the Meeting and to vote their shares.

The Meeting will be held at the American Stock Exchange, 86 Trinity Place, New York, NY 10006 at 11:00 a.m. local time.

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that it has signed an agreement with NTRU Cryptosystems, Inc. to exclusively represent NTRU's trusted computing and embedded security products in the Korean market. NTRU, a leading provider of embedded security software solutions, is a developer of fast, low-footprint public key cryptography.

Competitive Technologies, Inc. (AMEX:CTT - News) announced today that it has successfully reclaimed rights to its sexual dysfunction technology by terminating the license it had previously granted to Palatin Technologies, Inc. (AMEX:PTN - News). CTT now has complete control over license rights to the PT-14 sexual dysfunction technology. PTN has agreed to pay CTT an amount of $800,000 within one business day.

"CTT is continuing discussions with major pharmaceutical companies interested in licensing this innovative technology,'' said John B. Nano, CTT's Chairman, President and CEO. "CTT has always defended the patent rights of our clients, and will continue to do so. We are glad to bring this matter to a successful conclusion and to be able to focus on potential development of this technology by a major pharmaceutical company.''